Your browser doesn't support javascript.
loading
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps, Francesco; van de Kamp, Maaike W; Mayr, Roman; Bostrom, Peter J; Shariat, Shahrokh F; Hippe, Katrin; Bertz, Simone; Neuzillet, Yann; Sanders, Joyce; Otto, Wolfgang; van der Heijden, Michiel S; Jewett, Michael A S; Stöhr, Robert; Zlotta, Alexandre R; Trombetta, Carlo; Eckstein, Markus; Mertens, Laura S; Burger, Maximilian; Soorojebally, Yanish; Wullich, Bernd; Bartoletti, Riccardo; Radvanyi, François; Pavan, Nicola; Sirab, Nanour; Mir, M Carmen; Pouessel, Damien; van der Kwast, Theo H; Hartmann, Arndt; Lotan, Yair; Bussani, Rossana; Allory, Yves; van Rhijn, Bas W G.
Afiliação
  • Claps F; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • van de Kamp MW; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Mayr R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Bostrom PJ; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Shariat SF; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Hippe K; Department of Urology, Turku University Hospital and University of Turku, Turku, Finland.
  • Bertz S; Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA.
  • Neuzillet Y; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
  • Sanders J; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Otto W; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
  • van der Heijden MS; Department of Pathology, University Medical Center - Regensburg, Regensburg, Germany.
  • Jewett MAS; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Stöhr R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Zlotta AR; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Trombetta C; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • Eckstein M; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Mertens LS; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Burger M; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Soorojebally Y; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Wullich B; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Bartoletti R; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Radvanyi F; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Pavan N; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Sirab N; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Mir MC; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Pouessel D; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • van der Kwast TH; Department of Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Hartmann A; Unit of Urology, Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy.
  • Lotan Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • Bussani R; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Allory Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • van Rhijn BWG; Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain.
BJU Int ; 132(2): 170-180, 2023 08.
Article em En | MEDLINE | ID: mdl-36748180
ABSTRACT

OBJECTIVES:

To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC). MATERIALS AND

METHODS:

We analysed a multi-institutional cohort of 1082 patients treated with upfront RC for cT1-4aN0M0 urothelial BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect of different VHs on DSS in overall cohort and three stage-based analyses. The stages were defined as 'organ-confined' (≤pT2N0), 'locally advanced' (pT3-4N0) and 'node-positive' (pTanyN1-3).

RESULTS:

Overall, 784 patients (72.5%) had pure urothelial carcinoma (UC), while the remaining 298 (27.5%) harboured a VH. Squamous differentiation was the most common VH, observed in 166 patients (15.3%), followed by micropapillary (40 patients [3.7%]), sarcomatoid (29 patients [2.7%]), glandular (18 patients [1.7%]), lymphoepithelioma-like (14 patients [1.3%]), small-cell (13 patients [1.2%]), clear-cell (eight patients [0.7%]), nested (seven patients [0.6%]) and plasmacytoid VH (three patients [0.3%]). The median follow-up was 2.3 years. Overall, 534 (49.4%) disease-related deaths occurred. In uni- and multivariable analyses, plasmacytoid and small-cell VHs were associated with worse DSS in the overall cohort (both P = 0.04). In univariable analyses, sarcomatoid VH was significantly associated with worse DSS, while lymphoepithelioma-like VH had favourable DSS compared to pure UC. Clear-cell (P = 0.015) and small-cell (P = 0.011) VH were associated with worse DSS in the organ-confined and node-positive cohorts, respectively.

CONCLUSIONS:

More than 25% of patients harboured a VH at time of RC. Compared to pure UC, clear-cell, plasmacytoid, small-cell and sarcomatoid VHs were associated with worse DSS, while lymphoepithelioma-like VH was characterized by a DSS benefit. Accurate pathological diagnosis of VHs may ensure tailored counselling to identify patients who require more intensive management.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda